BAP1 maintains HIF-dependent interferon beta induction to suppress tumor growth in clear cell renal cell carcinoma-Reference-Cited by-同舟云学术

BAP1 maintains HIF-dependent interferon beta induction to suppress tumor growth in clear cell renal cell carcinoma

Published:2022-10 Issue: Volume:547 Page:215885
ISSN:0304-3835
Container-title:Cancer Letters
language:en
Short-container-title:Cancer Letters

Author:

Langbein Lauren E.^ORCID,El Hajjar Rayan,He Shen,Sementino Eleonora,Zhong Zhijiu,Jiang Wei,Leiby Benjamin E.,Li Li,Uzzo Robert G.,Testa Joseph R.,Yang Haifeng^ORCID

Funder

National Institutes of Health

International Association of Heat and Frost Insulators and Allied Workers

US Department of Defense

National Cancer Institute

Kidney Cancer Research Alliance

Kidney Cancer Association

Pennsylvania Department of Health

VHL Alliance

Sidney Kimmel Comprehensive Cancer Center

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference56 articles.

1. Cancer statistics, 2021. CA;Siegel;A Cancer J. Clin.,2021

2. Integrating immunotherapy into the management of renal cell carcinoma;Zibelman;J. Natl. Compr. Cancer Netw.,2017

3. HIF2 inhibitor joins the kidney cancer armamentarium;Kaelin;J. Clin. Oncol.,2018

4. Targeting the HIF2-VEGF axis in renal cell carcinoma;Choueiri;Nat. Med.,2020

5. Systemic therapy for metastatic renal-cell carcinoma;Choueiri;N. Engl. J. Med.,2017

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. VHL synthetic lethality screens uncover CBF-β as a negative regulator of STING;2024-09-06

2. Understanding the intersection between placental development and cancer: Lessons from the tumor suppressor BAP1;Communications Biology;2024-08-27

3. UCHL5 is a putative prognostic marker in renal cell carcinoma: a study of UCHL family;Molecular Biomedicine;2024-07-22

4. The role of cytoreductive nephrectomy in metastatic renal cell carcinoma in immune-oncology era (SEVURO-CN): study protocol for a multi-center, prospective, randomized trial;Trials;2024-07-03

5. PD-1 inhibitor plus oncolytic vaccinia virus is a safe and effective treatment option for metastatic renal cell carcinoma;Cancer Cell International;2024-01-30